Detalhe da pesquisa
1.
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
Cell
; 183(1): 158-168.e14, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979941
2.
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination.
Immunity
; 55(9): 1732-1746.e5, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35961317
3.
Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age.
Proc Natl Acad Sci U S A
; 120(12): e2220320120, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36917669
4.
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine.
Mol Med
; 28(1): 54, 2022 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35562666
5.
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
Mol Med
; 28(1): 20, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135470
6.
Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency.
J Clin Immunol
; 42(4): 716-727, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35290571
7.
The Karolinska KI/K COVID-19 Immune Atlas: An open resource for immunological research and educational purposes.
Scand J Immunol
; : e13195, 2022 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35652743
8.
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.
Blood
; 140(22): 2403-2407, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150168
9.
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.
Haematologica
; 109(2): 646-651, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646668
10.
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
Haematologica
; 107(4): 1000-1003, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045694
11.
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.
J Hematol
; 12(4): 170-175, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37692865
12.
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID.
EBioMedicine
; 94: 104700, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37453361
13.
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
EBioMedicine
; 74: 103705, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861491